Velpatasvir

DRUG5 trials

Sponsors

Gilead Sciences, Valme University Hospital, Radboud University Medical Center, M.D. Anderson Cancer Center

Conditions

Chronic Hepatitis C InfectionChronic Hepatitis C VirusHepatitis CHepatitis C VirusLiver CancerSwallowing Disorder

Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

CompletedNCT01740791

Gilead SciencesChronic Hepatitis C Virus

Start: 2012-11-06End: 2014-01-24Updated: 2020-12-16

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

CompletedNCT02002767

Gilead SciencesHepatitis C Virus

Start: 2013-12-16End: 2014-06-09Updated: 2020-11-16

Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.

CompletedNCT03513393

Radboud University Medical CenterHepatitis C, Swallowing Disorder

Start: 2018-08-01End: 2018-12-01Updated: 2020-10-19

Phase 4

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

TerminatedNCT05717400

M.D. Anderson Cancer CenterLiver Cancer

Start: 2023-03-17End: 2024-08-29Updated: 2024-12-31

Unknown Phase

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

CompletedNCT02333292

Valme University HospitalChronic Hepatitis C Infection

Start: 2014-12-31End: 2017-06-30Updated: 2022-06-29

Related Papers

Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

Journal of Antimicrobial Chemotherapy2023-09-064 citations

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV‐infected people on opioid agonist therapy

Journal of Viral Hepatitis2021-03-15

Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.

2019-03-0843 citations

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

Antimicrobial Agents and Chemotherapy2016-06-2983 citations